Atacicept Slowed Kidney Decline in Nephropathy Study
Adults with IgA nephropathy experienced significantly preserved kidney function over two years in a new clinical trial.
Updated on Sept. 22, 2026 in Diabetes
Live Poll
Do you trust that new clinical trial breakthroughs for chronic conditions provide meaningful long-term health improvements?
In the Phase 3 ORIGIN 3 study, the experimental drug atacicept slowed the rate of kidney function loss in 428 adults with primary IgA nephropathy. These results suggest a potential new treatment pathway for patients facing this progressive condition.
Why it matters
IgA nephropathy can lead to permanent kidney damage, and these findings represent a significant reduction in the risk of progression toward dialysis or transplant. The study provides critical evidence regarding the drug's ability to maintain kidney function over a two-year period.
In a Phase 3 trial of 428 adults, the atacicept group showed an annualized eGFR slope of -0.6 mL/min/1.73m2, compared to -5.6 mL/min/1.73m2 for those receiving a placebo. These results demonstrate a clear difference in kidney function preservation over 104 weeks.
The players
Vera Therapeutics
A biotechnology company focused on developing treatments for immunological diseases, including IgA nephropathy.
FDA
The United States federal agency responsible for regulating pharmaceuticals and approving new drug therapies.
The details
Atacicept works by inhibiting the activity of two specific cytokines, B-cell activating factor and a proliferation-inducing ligand. These proteins are heavily implicated in the pathogenesis of IgA nephropathy, a condition where immune complexes damage the kidneys. By blocking these signals, the treatment aims to dampen the immune response that drives progressive kidney function decline.
Timeline
52 weeks was the duration for the initial mean eGFR change measurement.
104 weeks was the timeframe for the annualized eGFR slope and progression risk analysis.
Q4 2026 is the planned date for the supplemental Biologics License Application submission.
Health Landscape
The ORIGIN 3 study marks an evolution in the treatment landscape for IgA nephropathy by targeting specific immune pathways rather than general inflammation. This approach adds to the growing pipeline of biologics aimed at preventing kidney failure in patients with autoimmune kidney disease.
If you are living with IgA nephropathy, these results are worth discussing with your nephrologist to understand how evolving biologic therapies may fit into your long-term care plan. Pay close attention to future regulatory updates regarding treatment options as they move toward potential approval.
The takeaway
The ORIGIN 3 study indicates that targeted immune modulation could significantly slow the progression of IgA nephropathy. Patients should continue to monitor their eGFR levels regularly and speak with their physician about emerging clinical trial data and treatment advancements.
Further reading
Learn more about the latest research on Diabetes and kidney complications.
Source note: This article includes information reported by Renal and Urology News.
Live Poll
Do you trust that new clinical trial breakthroughs for chronic conditions provide meaningful long-term health improvements?
